This is my new blog about a product / treatment I just read about. It’s called PL-6983 and is in development to treat female sexual arousal disorder (FSAD) and eventually erectile dysfunction (ED) as well.
The company developing it is Palatin Technologies and PL-6983 is a second attempt at such a drug. Their first attempt was with a drug initially called PT-141 and then formally named ‘Bremelanotide’… much like PL-6983 will eventually be given a real name.
Unfortunately the FDA did not approve Palatin’s application for Bremelanotide to be used as a treatment for ED, citing concerns about high blood pressure in some people who tested it. However it’s been commented here and there that it’s a bit of a double standard when you consider that Viagra WAS approved and it can cause LOW blood pressure in some people.
So Palatin has now moved onto a slightly different compound that apparently causes less instances or less significant blood pressure concerns in the rats (or whatever) that they’ve tested it on.
I intend to use this blog to follow the progress of PL-6983’s clinical trials and it (hopefully) eventual approval by the FDA.
Additional resources include:
- Palatin Technologies: the developer of PL-6983 and Bremelanotide
- The Bremelanotide Bulletin: a periodically updated website / newsletter with info about Bremelanotide, PL-6983, and similar treatments in development
- PL-6983.com: Obviously a site dedicated to this new treatment. Not much there as of the time of this writing, but likely will once clinical trials begin.
Tags: bremelanotide, ed, fsad, pl-6983
September 13, 2008 at 10:00 pm
Thre are no news on PL-6983 or bremelanotide in Palatin Technologies web-site.
Why is that? It is a rather not positive hint.
Yours,
Dr. Albert Bozzo
September 15, 2008 at 6:39 pm
Hi Dr Bozzo.
I dug around and do see a page for PL-6983 on Palatin Technologies’ site here: http://www.palatin.com/products/6983.asp
And one for Bremelanotide here: http://www.palatin.com/products/bremelanotide.asp
However keep in mind that Bremelanotide is no longer officially being pursued as a treatment for sexual dysfunction… it’s being tested as an “improvement in survival and prevention of organ dysfunction in patients with traumatic injuries resulting in hemorrhagic shock”.
…but, if approved for that use, then I *think* there’s precedent for a doctor to prescribe it for other uses as well (hint hint). Not sure about that belief, but it’s something I’ve read elsewhere that makes sense to me.
But if you’re commenting on the lack of new news about those two, then we’ll have to remain patient as they are just entering phase 1 trials, which always seems to require a long “ramp up” period.
Once they start those clinical trials I’ll definitely post about it here.
Thanks for commenting!